• 1
    Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, Sayada C, et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996; 34: 8083.
  • 2
    Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 15541568.
  • 3
    Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986; 324: 163166.
  • 4
    Compton J. Nucleic acid sequence-based amplification. Nature 1991; 350: 9192.
  • 5
    Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991; 24: 197200.
  • 6
    Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31 (Suppl 1): 5460.
  • 7
    Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3: 7578.
  • 8
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103107.
  • 9
    Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994999.
  • 10
    Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 1999; 31: 593597.
  • 11
    Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000; 242: 5584.
  • 12
    Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, et al. Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002; 36: 211218.
  • 13
    Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000; 40: 11981202.
  • 14
    Lee SR, Peterson J, Niven P, Bahl C, Page E, DeLeys R, Giordano-Schmidt D, et al. Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of “window-phase” blood donations. Vox Sang 2001; 80: 1923.
  • 15
    Farci P, Alter HJ, Wøng D, Miller RH, Shih JW, Jett B, Purcell RH. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98104.
  • 16
    Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992; 16: 877881.
  • 17
    Hino K, Sainokami S, Shimoda K, Niwa H, Iino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 1994; 39: 1927.
  • 18
    National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S10S.
    Direct Link:
  • 19
    Lefrere JJ, Guiramand S, Lefrere F, Mariotti M, Aumont P, Lerable J, Petit JC, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997; 175: 316322.
  • 20
    Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: 8795.
  • 21
    Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575577.
  • 22
    Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 17001702.
  • 23
    Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40: 11651168.
  • 24
    Pawlotsky JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C, Darthuy F, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 17341739.
  • 25
    Kobayashi M, Chayama K, Arase Y, Tsubota A, Saitoh S, Suzuki Y, Ikeda K, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6. J Gastroenterol 1999; 34: 505509.
  • 26
    Leruez-Ville M, Nguyen QT, Cohen P, Cocco S, Nouyou M, Ferriere F, Deny P. Large-scale analysis of hepatitis C virus serological typing assay: effectiveness and limits. J Med Virol 1998; 55: 1823.
  • 27
    Sandres K, Dubois M, Pasquier C, Puel J, Izopet J. Determination of HCV genotype using two antibody assays and genome typing. Eur J Clin Microbiol Infect Dis 2001; 20: 666669.
  • 28
    Prescott LE, Berger A, Pawlotsky JM, Conjeevaram P, Pike I, Simmonds P. Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays. J Med Virol 1997; 53: 237244.
  • 29
    Stuyver L, Wyseur A, van Arnhem W, Lunel F, Laurent-Puig P, Pawlotsky JM, Kleter B, et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995; 38: 137157.
  • 30
    Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 22592266.
  • 31
    Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol 1991; 72: 21052112.
  • 32
    Ansaldi F, Torre F, Bruzzone BM, Picciotto A, Crovari P, Icardi G. Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. J Med Virol 2001; 63: 1721.
  • 33
    Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, Roggendorf M. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000; 38: 35813584.
  • 34
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 818823.
  • 35
    Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA, WHO Collaborative Study Group. Vox Sang 1999; 76: 149158.
  • 36
    Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654659.
  • 37
    Pawlotsky JM, Martinot-Peignoux M, Poveda JD, Bastie A, Le Breton V, Darthuy F, Remire J, et al. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. J Virol Methods 1999; 79: 227235.
  • 38
    Yu ML, Chuang WL, Dai CY, Chen SC, Lin ZY, Hsieh MY, Wang LY, et al. Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV version 2.0 test. J Clin Microbiol 2000; 38: 29332939.
  • 39
    Gerken G, Rothaar T, Rumi MG, Soffredini R, Trippler M, Blunk MJ, Butcher A, et al. Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000; 38: 22102214.
  • 40
    Martinot-Peignoux M, Boyer N, Le Breton V, Le Guludec G, Castelnau C, Akremi R, Marcellin P. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology 2000; 31: 726729.
  • 41
    Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 41714179.
  • 42
    Pradat P, Chossegros P, Bailly F, Pontisso P, Saracco G, Sauleda S, Thursz M, et al. Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat 2000; 7: 203210.
  • 43
    Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Comparison of three quantitative HCV RNA assays. Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30: 441446.
  • 44
    Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology 1997; 26: 14.
  • 45
    EASL International Consensus Conference on Hepatitis C. Paris,26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956961.
  • 46
    Wejstal R, Widell A, Mansson AS, Hermodsson S, Norkrans G. Mother-to-infant transmission of hepatitis C virus. Ann Intern Med 1992; 117: 887890.
  • 47
    Roudot-Thoraval F, Pawlotsky JM, Thiers V, Deforges L, Girollet PP, Guillot F, Huraux C, et al. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing. Hepatology 1993; 17: 772777.
  • 48
    Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, Ujiie N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330: 744750.
  • 49
    Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. J Hepatol 1999; 31 (Suppl 1): 96100.
  • 50
    Hoofnagle JH. Therapy for acute hepatitis C. N Engl J Med 2001; 345: 14951497.
  • 51
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 52
    Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, Ramadori G, et al. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36 (Suppl. 1): 3.
  • 53
    Fried MW, Shiffman ML, Reddy K, Smith C, Marinos G, Gonć Lales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 54
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 14521457.
  • 55
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289293.